Kewaunee Scientific Corporation 2024 Form 10-K Summary
Business Context and Reporting Period
Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure, including casework, fume hoods, modular systems, workstations, biological safety cabinets, and epoxy-resin surfaces. Products are sold through dealers, international subsidiaries, and a national distributor to laboratory, healthcare, education, government, industrial, and research customers.
The filing is a Form 10-K for the fiscal year ended April 30, 2024. Although the request metadata refers to 2023 Q4, the filing reports full-year fiscal 2024 results and comparative fiscal 2023 results.
- Domestic employees: 556; international employees: 450.
- Order backlog at April 30, 2024: $155.6 million, versus $147.9 million at April 30, 2023; management estimates at least 88% will ship in fiscal 2025.
- Three domestic dealers represented approximately 45% of consolidated sales in fiscal 2024; two dealers and the national distributor represented approximately 42% in the business discussion.
- International sales represented approximately 33% of revenue; 29% of net sales were denominated in currencies other than the U.S. dollar.
Financial Highlights
| Metric | Fiscal 2024 | Fiscal 2023 | Change |
|---|---|---|---|
| Net sales | $203.8 million | $219.5 million | Down 7.2% |
| Gross profit | $52.1 million | $35.6 million | Up 46.2% |
| Gross margin | 25.5% | 16.2% | Up 930 basis points |
| Operating expenses | $33.8 million | $30.2 million | Up $3.5 million |
| Operating earnings | $18.3 million | $5.4 million | Up $12.9 million |
| Earnings before taxes | $13.1 million | $4.5 million | Up $8.6 million |
| Net earnings attributable to Kewaunee | $18.8 million | $0.7 million | Up $18.0 million |
| Diluted earnings per share | $6.38 | $0.25 | Up $6.13 |
| Cash flow from operations | $19.6 million | $(3.8) million | Improved $23.4 million |
| Capital expenditures | $4.4 million | $4.1 million | Up $0.2 million |
Domestic sales were $137.2 million, down 6.5%, primarily because the Company stopped selling directly to end users and therefore reduced freight, installation, and buyout revenue. International sales were $66.5 million, down 8.6%, reflecting large project deliveries in the prior-year period.
The gross-margin improvement was attributed primarily to improved domestic manufacturing productivity, cost containment, and pricing of new orders to reflect higher raw-material costs. Operating expenses increased due mainly to higher wages, benefits, incentive and stock compensation, governance costs, depreciation, bad-debt expense, and international operating expenses.
Fiscal 2024 net earnings benefited materially from a $5.9 million income-tax benefit, including a $6.6 million reduction in the domestic valuation allowance and a $3.9 million benefit related to prior-year unrecognized tax benefits associated with the pension settlement. Excluding these identified one-time tax benefits, income-tax expense was approximately $4.5 million, or 34.4% of pretax earnings.
Liquidity, Debt, and Balance Sheet
- Cash and cash equivalents: $23.3 million at April 30, 2024, versus $8.1 million at April 30, 2023.
- Total cash, cash equivalents, and restricted cash: $25.9 million, versus $13.8 million.
- Working capital: $56.0 million, versus $47.9 million; current ratio improved to 2.4-to-1.0 from 2.2-to-1.0.
- Revolving credit facility: $3.0 million outstanding under a $15.0 million facility, with $11.6 million of remaining borrowing capacity. The facility matures December 19, 2025 and bears interest at Term SOFR plus 4.10%; the stated rate was 9.54% at April 30, 2024.
- Sale-leaseback financing liability: $28.1 million, including $0.7 million classified as current and $27.4 million long term.
- Total liabilities: $78.6 million; total stockholders’ equity: $56.2 million.
- Fiscal 2024 financing cash outflows included $2.0 million of common-stock repurchases. No dividends were declared or paid during fiscal 2024 or fiscal 2023.
Management believes operating cash flow, supplemented as needed by borrowings under the revolving facility, will fund ongoing requirements and fiscal 2025 capital expenditures. Fiscal 2025 capital expenditures are expected to be approximately $4.0 million.
Material Changes Versus the Prior Comparable Period
- Revenue declined despite a higher backlog, reflecting reduced domestic non-product revenue and the absence of certain large international project deliveries recorded in fiscal 2023.
- Gross margin expanded substantially from 16.2% to 25.5% through productivity improvements, cost containment, and pricing actions.
- Operating cash flow turned positive, increasing from a $3.8 million use of cash to $19.6 million provided, aided by lower receivables and inventories and improved working-capital movements.
- The Company completed the annuitization of approximately $17.8 million of frozen pension obligations. This generated a $4.0 million settlement expense but eliminated future responsibility for the plans and related administrative costs.
- Deferred tax assets improved materially, with the domestic valuation allowance declining to approximately $0.9 million from $8.6 million.
- The Company repurchased 66,191 shares for approximately $2.0 million under a program authorizing up to 100,000 shares; 33,809 shares remained authorized for repurchase at April 30, 2024.
Outlook, Risks, Contingencies, and Unusual Items
Management states that demand is difficult to predict because the Company often serves as a subcontractor or supplier to dealers, and demand depends on laboratory and healthcare construction activity, project timing, pricing, and raw-material costs. Management believes the Company is operating more efficiently, has a healthy backlog, improved manufacturing capabilities, and benefits from end markets that continue to prioritize laboratory and healthcare investment.
- Major risks include construction delays, customer rescheduling, competitive bidding, fixed-price contracts, raw-material and labor inflation, supply-chain disruption, and inability to adjust production capacity quickly.
- Customer concentration is significant; loss of a major dealer or distributor could materially affect revenue and profit.
- International operations expose the Company to foreign-currency, political, regulatory, trade, tariff, geopolitical, and economic risks.
- Cybersecurity incidents or information-technology failures could disrupt manufacturing, shipping, customer transactions, and financial reporting. Management reported no cybersecurity risk that had materially affected or was reasonably likely to materially affect the Company as of the filing.
- Cash deposits may exceed FDIC insurance limits, creating potential liquidity exposure if a financial institution fails.
- Foreign bank guarantees totaling approximately $7.8 million had expiration dates extending through fiscal 2027 and were collateralized by certain Indian subsidiary assets.
- A new three-year lease with aggregate future payments of approximately $681,000 had not commenced as of April 30, 2024 and was expected to begin in fiscal 2025.
- Pending ordinary-course claims and legal proceedings were not expected by management to have a material adverse effect.
- The independent auditor issued an unqualified opinion and identified no critical audit matters. The Company is not required to obtain an external auditor attestation on internal control over financial reporting.
Investor Verification Priorities
- Verify the sustainability of the 25.5% gross margin and whether fiscal 2024 productivity and pricing benefits persist.
- Separate recurring earnings from the $5.9 million tax benefit and the $4.0 million pension-settlement expense.
- Monitor backlog conversion, project delays, customer rescheduling, and the concentration of sales among major channel partners.
- Review liquidity relative to the $28.1 million sale-leaseback financing liability, lease commitments, and the December 2025 revolving-credit maturity.
- Assess international execution, foreign-currency exposure, raw-material costs, tariffs, and supply-chain conditions.
- Confirm cash-flow conversion, accounts-receivable collections, retention amounts, and the expected $4.0 million fiscal 2025 capital-spending program.
- Evaluate the financial effect and remaining authorization under the share-repurchase program, as well as the absence of dividends.